Icariin (Ica), the main active component of Herba Epimedii, has been identified as an osteogenic and angiogenic phytomolecule. To develop a bioactive scaffold for enhancing bone repair, Ica was loaded into porous tricalcium phosphate (TCP) scaffolds, and the obtained porous Ica/TCP composites were investigated for treating osteonecrosis of the femoral head (ONFH) in a rabbit model. ONFH was histopathologically confirmed at two weeks after methylprednisolone acetate injection, and the rabbits were treated with porous Ica/TCP scaffolds (group A), porous TCP scaffolds (group B), and autogenous cancellous bone graft (group C). At 12 weeks, the amount of newly formed bone in group A increased significantly compared with that in group B (P = 0.003). The mean histological and radiological scores for repaired defects in group A were significantly higher than those in group B (P = 0.007, P = 0.029, respectively), but were lower than those in group C (P = 0.032, P = 0.046, respectively). In addition, the expression of vascular endothelial growth factor by immunohistochemical testing and real-time polymerase chain reaction in group A was significantly higher than that in group B (P = 0.002, P = 0.001, respectively), but was lower than that in group C (P = 0.034, P = 0.005, respectively). Therefore, Ica can be a promising osteogenic and angiogenic compound for repairing bone defects and preventing the collapse of the femoral head in ONFH.
MontMAZywielMGMarkerDR. The natural history of untreated asymptomatic osteonecrosis of the femoral head: a systematic literature review. J Bone Joint Surg Am2010; 92: 2165–2170.
2.
FukushimaWFujiokaMKuboT. Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res2010; 468: 2715–2724.
3.
OIssaKPivecRKapadiaBH. Osteonecrosis of the femoral head: the total hip replacement solution. Bone Joint J2013; 95: 46–50.
4.
MarkerDRSeylerTMMcGrathMS. Treatment of early stage osteonecrosis of the femoral head. J Bone Joint Surg Am2008; 90: 175–187.
5.
McGroryBJYork SallyCIorioR. Current practices of AAHKS members in the treatment of adult osteonecrosis of the femoral head. J Bone Joint Surg Am2007; 89: 1194–1204.
6.
CuiQBotchweyEA. Emerging ideas: treatment of precollapse osteonecrosis using stem cells and growth factors. Clin Orthop Relat Res2011; 469: 2665–2669.
7.
KangPShenBYangJ. Repairing defect and preventing collapse of canine femoral head using titanium implant enhanced by autogenous bone graft and rhBMP-2. Connect Tissue Res2007; 48: 171–179.
MiramondTCorrePBorgetP. Osteoinduction of biphasic calcium phosphate scaffolds in a nude mouse model. J Biomater Appl2014; 29: 595–604.
11.
Kroese-DeutmanHCRuhePQSpauwenPHM. Bone inductive properties of rhBMP-2 loaded porous calcium phosphate cement implants inserted at an ectopic site in rabbits. Biomaterials2005; 26: 1131–1138.
12.
NathSDLinhNTSadiasaA. Encapsulation of simvastatin in PLGA microspheres loaded into hydrogel loaded BCP porous spongy scaffold as a controlled drug delivery system for bone tissue regeneration. J Biomater Appl2014; 28: 1151–1163.
13.
SeehermanHJAzariKBidicS. rhBMP-2 delivered in a calcium phosphate cement accelerates bridging of critical-sized defects in rabbit radii. J Bone Joint Surg Am2006; 88: 1553–1565.
14.
HoshinoMEgiTTeraiH. Repair of long intercalated rib defects using porous beta-tricalcium phosphate cylinders containing recombinant human bone morphogenetic protein-2 in dogs. Biomaterials2006; 27: 4934–4940.
15.
GarrisonKRShemiltIDonellS. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev2010; 6: CD006950–CD006950.
16.
SimmondsMCBrownJVHeirsMK. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med2013; 158: 877–889.
17.
ZhaoBKatagiriTToyodaH. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem2006; 281: 23246–23253.
18.
SinghKAhmadiniaKParkDK. Complications of spinal fusion with utilization of bone morphogenetic protein: a systematic review of the literature. Spine2014; 39: 91–101.
19.
ZhangGQinLShiY. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. J Bone Miner Res2007; 22: 1072–1079.
20.
ZhuHMQinLGarneroP. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis. Osteoporos Int2012; 23: 1317–1327.
21.
ZhengDPengSYangSH. The beneficial effect of Icariin on bone is diminished in osteoprotegerin-deficient mice. Bone2012; 51: 85–92.
22.
MaHPMingLGGeBF. Icariin is more potent than genistein in promoting osteoblast differentiation and mineralization in vitro. J Cell Biochem2011; 112: 916–923.
23.
ZhaoJOhbaSShinkaiM. Icariin induces osteogenic differentiation in vitro in a BMP- and Runx2-dependent manner. Biochem Biophys Res Commun2008; 369: 444–448.
24.
MokSKChenWFLaiWP. Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. Br J Pharmacol2010; 159: 939–949.
25.
FanJBiLWuT. A combined chitosan/nano-size hydroxyapatite system for the controlled release of icariin. J Mater Sci Mater Med2012; 23: 399–407.
26.
ZhaoJOhbaSKomiyamaY. Icariin: a potential osteoinductive compound for bone tissue engineering. Tissue Eng Part A2010; 16: 233–243.
27.
ChungBHKimJDKimCK. Icariin stimulates angiogenesis by activating the MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways in human endothelial cells. Biochem Biophys Res Commun2008; 376: 404–408.
28.
ZhangXGuoYLiDX. The effect of loading icariin on biocompatibility and bioactivity of porous β-TCP ceramic. J Mater Sci Mater Med2011; 22: 371–379.
29.
WangXLXieXHZhangG. Exogenous phytoestrogenic molecule icaritin incorporated into a porous scaffold for enhancing bone defect repair. J Orthop Res2013; 31: 164–172.
30.
MiyanishiKYamamotoTIrisaT. Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone2002; 30: 185–190.
31.
KangPDPeiFXShenB. Lovastatin inhibits adipogenesis and prevents osteonecrosis in steroid-treated rabbits. Joint Bone Spine2008; 75: 696–701.
32.
KangPXieXTanZ. Repairing defect and preventing collapse of femoral head in a steroid-induced osteonecrotic of femoral head animal model using strontium-doped calcium polyphosphate combined BM-MNCs. J Mater Sci Mater Med2015; 26: 5402–5410.
33.
MontMAJonesLCEliasJJ. Strut-autografting with and without osteogentic protein-1: a preliminary study of a canine femoral head defect model. J Bone Join Surg Am2001; 83: 1013–1022.
34.
PeledEDavisMAxelmanE. Heparanase role in the treatment of avascular necrosis of femur head. Thromb Res2013; 131: 94–98.
35.
LiWSakaiTNishiiT. Distribution of TRAP-positive cells and expression of HIF-1alpha, VEGF, and FGF-2 in the reparative reaction in patients with osteonecrosis of the femoral head. J Orthop Res2009; 27: 694–700.
36.
KoJYWangFSWangCJ. Increased Dickkopf-1 expression accelerates bone cell apoptosis in femoral head osteonecrosis. Bone2010; 46: 584–591.
37.
ZalavrasCGLiebermanJR. Osteonecrosis of the femoral head: evaluation and treatment. J Am Acad Orthop Surg2014; 22: 455–464.
38.
StegenSvan GastelNCarmelietG. Bringing new life to damaged bone: the importance of angiogenesis in bone repair and regeneration. Bone2015; 70: 19–27.
39.
HsiehTPSheuSYSunJS. Icariin isolated from Epimedium pubescens regulates osteoblasts anabolism through BMP-2, SMAD4, and Cbfa1 expression. Phytomedicine2010; 17: 414–423.
40.
HsiehTPSheuSYSunJS. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis. Phytomedicine2011; 18: 176–185.
41.
ZhangLZhangXLiKF. Icariin promotes extracellular matrix synthesis and gene expression of chondrocytes in vitro. Phytother Res2012; 26: 1385–1392.
42.
ZhangXXuMSongL. Effects of compatibility of deproteinized antler cancellous bone with various bioactive factors on their osteogenic potential. Biomaterials2013; 34: 9103–9114.
43.
WernikeEMontjoventMOLiuY. VEGF incorporated into calcium phosphate ceramics promotes vascularisation and bone formation in vivo. Eur Cell Mater2010; 19: 30–40.
44.
KoizumiHYuJHashimotoR. Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells. FEBS Lett2010; 584: 2440–2444.
45.
XuHBHuangZQ. Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascul Pharmacol2007; 47: 18–24.
46.
ZhangXLiuTHuangY. Icariin: does it have an osteoinductive potential for bone tissue engineering?Phytother Res2014; 28: 498–509.
47.
SunZBWangJWXiaoH. Icariin may benefit the mesenchymal stem cells of patients with steroid-associated osteonecrosis by ABCB1-promoter demethylation: a preliminary study. Osteoporos Int2015; 26: 187–197.
48.
LiDYuanTZhangX. Icariin: a potential promoting compound for cartilage tissue engineering. Osteoarthr Cartil2012; 20: 1647–1656.
